

RECEIVED

JAN 28 2002

TECH CENTER 1600/2900 PATENT
DOCKET NO.: 2283/301

#2231P
1/28/02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant :	Leivan DeVeylder et al)	Examiner:	
Serial No. :	09/574,735)	C. Collins	
Conf. No. :	1507)	Art Unit:	
Filed :	May 18, 2000)	1638	
For :	CYCLIN-DEPENDENT KINASE INHIBITORS AND USES THEREOF)		
)		

RESPONSE TO RESTRICTION REQUIREMENT
UNDER 37 C.F.R. § 1.111 AND § 1.143

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated November 15, 2001, and in accordance with the provisions of 37 C.F.R. §§ 1.111 and 1.143, Applicants provisionally elect, with traverse, the subject matter of Group IV, claims 2, 5, 7-25, 27-31 and 36-57, drawn to methods comprising introducing into a plant cell a nucleic acid molecule of SEQ ID NO:1 encoding a cyclin-dependent kinase inhibitor (CKI) of SEQ ID NO:2, and to transgenic plants comprising said nucleotide sequence.

REMARKS

Claims 1-59 are present in the application and have been subjected to restriction by the Examiner under 35 U.S.C. § 121 (37 C.F.R. 1.142) as follows:

I. Claims 1, 3, 4, 6, 12, 26, 29, 34, 52, and 54, drawn to methods in a plant, comprising introducing into a plant cell a cyclin-dependent kinase inhibitor (CKI) of SEQ ID NO:2, classified in class 435, subclass 410;

II. Claims 1, 3, 4, 6, 12, 26, 28, 29, 34, 52, and 54, drawn to methods comprising introducing into a plant cell a cyclin-dependent kinase inhibitor (CKI) of SEQ ID NO: 4, classified in class 435, subclass 410;

G186477.1